FOI 25-0034 LD – ATAGI Evidence

Written by Claude Haiku 4.5 from the extracted text on 27 Feb 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

ATAGI's July 2021 clinical guidance (v6.0) on COVID-19 vaccination provided recommendations for Comirnaty (Pfizer) and AstraZeneca vaccines across population groups. Key updates included expanding Comirnaty eligibility to children aged 12-15 years with medical risk factors, Aboriginal and Torres Strait Islander children, and remote community residents. The guidance documented emerging safety signals: myocarditis and pericarditis rarely reported after Comirnaty (requiring deferral of further doses and cardiologist consultation for those with pre-existing cardiac conditions); immune thrombocytopenia, Guillain-Barré Syndrome, and capillary leak syndrome reported after AstraZeneca (with capillary leak syndrome established as a new contraindication). Mixed vaccination schedules were recommended for specific populations including returned travellers and those experiencing serious adverse events after first doses.